Do analysts recommend AMRN or HRTX?

Heron Therapeutics has a consensus target price of $2.50, indicating a potential upside of 448.49%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is AMRN or HRTX more profitable?

Amarin has a net margin of -15.51% compared to Heron Therapeutics' net margin of -20.53%. Amarin's return on equity of -2.99% beat Heron Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Heron Therapeutics -20.53% -7,747.30% -8.94%

Heron Therapeutics (HRTX) Competitors

$0.46 0.00 (-0.70%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.04%)

As of 07/24/2026 07:24 PM Eastern

Compare

HRTX vs. IRD, AMRN, BCYC, EDIT, and ELDN

Should you buy Heron Therapeutics stock or one of its competitors? MarketBeat compares Heron Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heron Therapeutics include Opus Genetics (IRD), Amarin (AMRN), Bicycle Therapeutics (BCYC), Editas Medicine (EDIT), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry.

How does Heron Therapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Heron Therapeutics has a net margin of -20.53% compared to Opus Genetics' net margin of -892.36%. Opus Genetics' return on equity of -338.88% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Opus Genetics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Heron Therapeutics has higher revenue and earnings than Opus Genetics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	17.91	-$49.59M	-$1.33	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Opus Genetics currently has a consensus price target of $10.77, indicating a potential upside of 249.65%. Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 448.49%. Given Heron Therapeutics' higher possible upside, analysts plainly believe Heron Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.82
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Opus Genetics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Opus Genetics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Opus Genetics' score of 1.07 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Opus Genetics	Positive
Heron Therapeutics	Very Positive

Summary

Heron Therapeutics beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, Amarin had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for Amarin and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Amarin's score of 0.19 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Neutral
Heron Therapeutics	Very Positive

Heron Therapeutics has a consensus target price of $2.50, indicating a potential upside of 448.49%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$216.76M	1.31	-$38.80M	-$0.65	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

22.3% of Amarin shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Amarin has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Amarin has a net margin of -15.51% compared to Heron Therapeutics' net margin of -20.53%. Amarin's return on equity of -2.99% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Summary

Heron Therapeutics beats Amarin on 9 of the 17 factors compared between the two stocks.

How does Heron Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Bicycle Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 2 mentions for Bicycle Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Bicycle Therapeutics' score of 1.75 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Very Positive
Heron Therapeutics	Very Positive

Bicycle Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 261.76%. Heron Therapeutics has a consensus price target of $2.50, suggesting a potential upside of 448.49%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has a net margin of -20.53% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Heron Therapeutics has higher revenue and earnings than Bicycle Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$3.15	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

Summary

Bicycle Therapeutics and Heron Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 107.69%. Heron Therapeutics has a consensus target price of $2.50, suggesting a potential upside of 448.49%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Editas Medicine had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Editas Medicine's score of 1.07 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Editas Medicine	Positive
Heron Therapeutics	Very Positive

Heron Therapeutics has a net margin of -20.53% compared to Editas Medicine's net margin of -281.59%. Editas Medicine's return on equity of -677.39% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Heron Therapeutics has higher revenue and earnings than Editas Medicine. Heron Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.28	-$160.06M	-$1.23	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Summary

Heron Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Heron Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Heron Therapeutics	$150.71M	0.57	-$20.19M	-$0.18	N/A

Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

In the previous week, Eledon Pharmaceuticals had 4 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Eledon Pharmaceuticals and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.89 beat Eledon Pharmaceuticals' score of 0.57 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eledon Pharmaceuticals	Positive
Heron Therapeutics	Very Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Eledon Pharmaceuticals currently has a consensus price target of $9.67, suggesting a potential upside of 170.02%. Heron Therapeutics has a consensus price target of $2.50, suggesting a potential upside of 448.49%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eledon Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Eledon Pharmaceuticals' return on equity of -116.97% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%

Summary

Heron Therapeutics beats Eledon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$86.27M	$3.06B	$6.86B	$12.25B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-2.53	20.29	27.14	23.64
Price / Sales	0.57	485.21	517.01	89.03
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	6.51	4.13	10.28	6.07
Net Income	-$20.19M	$65.94M	$3.60B	$331.99M
7 Day Performance	-3.17%	-4.16%	-1.27%	-0.63%
1 Month Performance	11.17%	-3.76%	-0.37%	-2.00%
1 Year Performance	-76.14%	9.94%	18.30%	13.62%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	1.9804 of 5 stars	$0.46 -0.7%	$2.50 +448.5%	-76.0%	$86.27M	$150.71M	N/A	300	Positive News
IRD Opus Genetics	2.8506 of 5 stars	$3.79 -0.5%	$10.77 +184.1%	+154.5%	$312.94M	$14.20M	N/A	14
AMRN Amarin	1.5168 of 5 stars	$14.50 -1.4%	N/A	-12.6%	$304.07M	$213.65M	N/A	360	News Coverage Upcoming Earnings Analyst Downgrade
BCYC Bicycle Therapeutics	3.0228 of 5 stars	$4.31 -0.9%	$14.00 +224.8%	-55.0%	$301.93M	$72.86M	N/A	240	News Coverage Positive News
EDIT Editas Medicine	3.0825 of 5 stars	$3.07 -3.0%	$5.40 +76.2%	-20.2%	$300.09M	$40.52M	N/A	230	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. IRD, AMRN, BCYC, EDIT, and ELDN

How does Heron Therapeutics compare to Opus Genetics?

Summary

How does Heron Therapeutics compare to Amarin?

Summary

How does Heron Therapeutics compare to Bicycle Therapeutics?

Summary

How does Heron Therapeutics compare to Editas Medicine?

Summary

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. IRD, AMRN, BCYC, EDIT, and ELDN

How does Heron Therapeutics compare to Opus Genetics?

Is IRD or HRTX more profitable?

Which has more risk and volatility, IRD or HRTX?

Which has stronger valuation & earnings, IRD or HRTX?

Do institutionals & insiders believe in IRD or HRTX?

Do analysts prefer IRD or HRTX?

Does the media prefer IRD or HRTX?

Summary

How does Heron Therapeutics compare to Amarin?

Does the media refer more to AMRN or HRTX?

Do analysts recommend AMRN or HRTX?

Which has stronger earnings & valuation, AMRN or HRTX?

Do institutionals and insiders believe in AMRN or HRTX?

Which has more risk and volatility, AMRN or HRTX?

Is AMRN or HRTX more profitable?

Summary

How does Heron Therapeutics compare to Bicycle Therapeutics?

Does the media favor BCYC or HRTX?

Which has more volatility & risk, BCYC or HRTX?

Do insiders and institutionals have more ownership in BCYC or HRTX?

Do analysts prefer BCYC or HRTX?

Is BCYC or HRTX more profitable?

Which has stronger earnings & valuation, BCYC or HRTX?

Summary

How does Heron Therapeutics compare to Editas Medicine?

Do analysts rate EDIT or HRTX?

Does the media prefer EDIT or HRTX?

Is EDIT or HRTX more profitable?

Do insiders and institutionals hold more shares of EDIT or HRTX?

Which has preferable earnings & valuation, EDIT or HRTX?

Which has more risk & volatility, EDIT or HRTX?

Summary

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Which has preferable earnings & valuation, ELDN or HRTX?

Which has more volatility and risk, ELDN or HRTX?

Does the media refer more to ELDN or HRTX?

Do institutionals & insiders believe in ELDN or HRTX?

Do analysts prefer ELDN or HRTX?

Is ELDN or HRTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools